Literature DB >> 28677048

A new perspective for nuclear medicine: expanding the indications for PSMA targeted imaging and therapy.

Frederik A Verburg1, Markus Luster2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28677048     DOI： 10.1007/s00259-017-3767-4

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  32 in total

1.  (68)Ga-PSMA PET/CT imaging of metastatic clear cell renal cell carcinoma.

Authors:  Emre Demirci; Meltem Ocak; Levent Kabasakal; Clemens Decristoforo; Zübeyir Talat; Metin Halaç; Bedii Kanmaz
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-04-23       Impact factor: 9.236

2.  Molecular imaging using PSMA PET/CT versus multiparametric MRI for initial staging of prostate cancer: comparing apples with oranges?

Authors:  Felix M Mottaghy; Alexander Heinzel; Frederik A Verburg
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-04-27       Impact factor: 9.236

3.  Imaging of Prostate-Specific Membrane Antigen Expression in Metastatic Differentiated Thyroid Cancer Using 68Ga-HBED-CC-PSMA PET/CT.

Authors:  Susanne Lütje; Benedikt Gomez; Joseph Cohnen; Lale Umutlu; Martin Gotthardt; Thorsten D Poeppel; Andreas Bockisch; Sandra Rosenbaum-Krumme
Journal:  Clin Nucl Med       Date:  2017-01       Impact factor: 7.794

4.  Comparison of PSMA-HBED and PSMA-I&T as diagnostic agents in prostate carcinoma.

Authors:  Michael McCarthy; Tiffany Langton; Divesh Kumar; Andrew Campbell
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-05-04       Impact factor: 9.236

5.  Incidental Detection of Follicular Thyroid Carcinoma in 68Ga-PSMA PET/CT Imaging.

Authors:  Sait Sager; Betül Vatankulu; Lebriz Uslu; Kerim Sönmezoglu
Journal:  J Nucl Med Technol       Date:  2016-03-10

6.  Follicular Thyroid Adenoma Showing Avid Uptake on 68Ga PSMA-HBED-CC PET/CT.

Authors:  Gowri L Kanthan; James Drummond; Geoff Paul Schembri; Michael A Izard; Edward Hsiao
Journal:  Clin Nucl Med       Date:  2016-04       Impact factor: 7.794

7.  PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions.

Authors:  A Afshar-Oromieh; A Malcher; M Eder; M Eisenhut; H G Linhart; B A Hadaschik; T Holland-Letz; F L Giesel; C Kratochwil; S Haufe; U Haberkorn; C M Zechmann
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-11-24       Impact factor: 9.236

8.  Expression of prostate specific membrane antigen (PSMA) in prostatic adenocarcinoma and prostatic intraepithelial neoplasia.

Authors:  C Marchal; M Redondo; M Padilla; J Caballero; I Rodrigo; J García; J Quian; D G Boswick
Journal:  Histol Histopathol       Date:  2004-07       Impact factor: 2.303

9.  Comparison of [(18)F]DCFPyL and [ (68)Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer.

Authors:  Markus Dietlein; Carsten Kobe; Georg Kuhnert; Simone Stockter; Thomas Fischer; Klaus Schomäcker; Matthias Schmidt; Felix Dietlein; Boris D Zlatopolskiy; Philipp Krapf; Raphael Richarz; Stephan Neubauer; Alexander Drzezga; Bernd Neumaier
Journal:  Mol Imaging Biol       Date:  2015-08       Impact factor: 3.488

10.  Early side effects and first results of radioligand therapy with (177)Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study.

Authors:  Hojjat Ahmadzadehfar; Kambiz Rahbar; Stefan Kürpig; Martin Bögemann; Michael Claesener; Elisabeth Eppard; Florian Gärtner; Sebastian Rogenhofer; Michael Schäfers; Markus Essler
Journal:  EJNMMI Res       Date:  2015-06-20       Impact factor: 3.138
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.